Abbonarsi

Cardiovascular risk and outcomes in symptomatic patients with suspected coronary artery disease and non coronary vascular disease: A report from the PROMISE trial - 30/10/21

Doi : 10.1016/j.ahj.2021.07.010 
Sreekanth Vemulapalli, MD a, b, , Amanda Stebbins, MS a, W. Schuyler Jones, MD a, b, J. Antonio Gutierrez, MD, MHS a, b, Manesh R. Patel, MD a, b, Rowena J. Dolor, MD, MHS a, c, Patricia A. Pellikka, MD d, Brooke Alhanti, PhD a, Udo Hoffmann, MD e, Pamela S. Douglas, MD a, b
a Duke Clinical Research Institute, Durham, NC 
b Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC 
c Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC 
d Department of Cardiovascular Medicine, Mayo Clinic School of Medicine, Rochester, MN 
e Massachusetts General Hospital, Boston, MA 

Reprint requests: Sreekanth Vemulapalli, MD, Duke University Hospital, Box 3026, Durham, NC 27710.Duke University HospitalBox 3026DurhamNC27710

Riassunto

Background

Non-coronary vascular disease (NCVD) is associated with adverse cardiovascular events. Little is known about physician risk assessment, prevalence of coronary artery disease (CAD), cardiac catheterization, and the performance of the atherosclerotic cardiovascular disease (ASCVD) risk score in patients with NCVD.

Methods

Retrospective analysis of outpatients with angina and no known CAD from the PROMISE trial. NCVD included carotid artery stenosis ≥50%, or history of stroke or peripheral artery disease. Multivariable models of physician estimates of the probability of obstructive CAD, prevalence of non-obstructive and obstructive CAD, referral to cardiac catheterization, and all-cause death/myocardial infarction/unstable angina were performed.

Results

Among 10,001 patients in the PROMISE trial, 379 (3.8%) patients had NCVD. Only 8.5% of participants with NCVD were categorized as high-risk for obstructive CAD by physicians, though 15.5% (25/161) had obstructive CAD in those randomized to coronary computed tomography (CTA). NCVD was independently associated with non-obstructive (aOR = 1.58; 95% CI 1.18-2.61; P = .006) but not obstructive CAD by CTA. Adjusted referral to cardiac catheterization was similar with and without NCVD (aOR 1.04; 95% CI 0.88-1.94, P = .19). NCVD was associated with an increased risk of all-cause death/MI/UA (aOR 2.03; 95% CI 1.37-3.01, P < .001). There was no interaction between NCVD status and ASCVD risk score.

Conclusions

Among patients with NCVD and angina, NCVD had increased adjusted risks of CAD and adverse outcomes which were not well described by ASCVD risk score and were underrecognized by physicians. Increased awareness and better risk stratification tools for patients with NCVD may be necessary to recognize the associated CV risk and optimize diagnostic testing and therapies.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 This paper was handled by Guest Editor (Debabrata Mukherjee, MD. Clin. Inv.).


© 2021  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 242

P. 82-91 - Dicembre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis
  • Ghadeer K. Dawwas, Geoffrey D. Barnes, Eric Dietrich, Adam Cuker, Charles E. Leonard, Michael V. Genuardi, James D. Lewis
| Articolo seguente Articolo seguente
  • Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms
  • Nikola Pavlovic, Gian-Battista Chierchia, Vedran Velagic, Jean Sylvain Hermida, Stewart Healey, Giuseppe Arena, Nicolas Badenco, Christian Meyer, Jian Chen, Saverio Iacopino, Frédéric Anselme, Lukas Dekker, Fernando Scazzuso, Douglas L Packer, Carlo de Asmundis, Heinz-Friedrich Pitschner, Fabio Di Piazza, Rachelle E Kaplon, Malte Kuniss, Cryo-FIRST Investigators

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.